CrownVivo™ antibodies are functional grade isotype controls, manufactured specifically for in vivo animal studies.
In vivo Grade Isotype Control Antibodies
MESACUP™ anti-MDA5 TEST
Biomarker of dermatomyositis with rapidly progressive interstitial lung disease Clinically amyopathic dermatomyositis (CADM), dermatomyositis without muscle weakness, is associated with elevated rates of rapidly progressive interstitial lung disease (RP-ILD), which is extremely resistant to treatment. The prognosis is poor after
TCR Tetramers
A TCR Tetramer is a reagent prepared by tetramerising biotinylated antigen-specific TCRs with the help of phycobiliprotein-labelled streptavidin.
Non-classical MHC Tetramers
Non-classical Major Histocompatibility Complex (MHC) molecules are non-polymorphic proteins implicated in both innate and adaptive immune responses.1,2 While classical MHCs present antigens to CD8+/CD4+ cells for further immune processing, non-classical MHCs also mediate activation or inhibition in natural killer (NK) cells.3 MBL
CD1d
CD1d molecules are non-polymorphic MHC class I-like proteins. These are a type of non-classical MHCs. They present phospholipid and glycosphingolipid antigens to invariant Natural Killer T (iNKT) cells, a subset of CD1d-restricted T cells. This axis is involved in the
MHC Class II Tetramers
T cell receptors (TCRs) expressed on the surface of T cells specifically recognise and bind to complexes of major histocompatibility complex (MHC) molecules and peptide fragments. CD4+ T cells, which include helper and regulatory T cells, recognise complexes of MHC class
MHC Class I Tetramers
T cell receptors (TCRs) expressed on the surface of T cells specifically recognise and bind to complexes of major histocompatibility complex (MHC) molecules and peptide fragments expressed on the surface of antigen-presenting cells. CD8+ T cells, also called cytotoxic T
Exploring Single Domain Antibodies for Tauopathy Treatment
Researchers at New York University Grossman School of Medicine, led by Erin E. Congdon, have explored the potential of single-domain antibodies (sdAbs) in treating tauopathies, including Alzheimer’s disease. The results of their study were recently published in The Lancet® and focused
Nanobody (VHH) Development Service
Leadgene Biomedical offers a Nanobody (VHH Antibody) Development Service, now available at special pricing when you contact us!
NanOZ-LNP Lipid Nanoparticles
OZ Biosciences provides custom and stock lipid nanoparticles (LNP) delivery systems.